Campaign Opens Up Collaboration Opportunities Around Rare Disease Diversity
NORD’s director of membership talks about how companies focused on rare diseases can partner with often under-resourced non-profits on diversity initiatives.
You may also be interested in...
Early on, the company committed to transparency while making sure its Phase III vaccine study enrolled a population reflective of the US as a whole. Moderna talks to Scrip about the experience.
Panel discussion illustrated how decentralized approaches can expand the possibilities of studies in rare diseases, such as cancers with rare genomic alterations.